Clinical Proteomics in Oncology

CPO 2008

July 3rd and 4th, 2008 - Dijon, France

July 3rd, 2008

9h 30 – 10 h 00 Welcome

Part # 1 - Proteomic in clinical studies

Plenary lecture

DW Speicher (USA):

The Needle-In-The-Haystack Challenge of Cancer Biomarker Discovery and Validation: Best Haystack? Best Tools? Are Needles Really Present?

ON Jensen (Denmark):

Reproducibility of Mass Spectrometry Based Protein Profiles for Diagnosis of Breast Cancer across Clinical Studies

E Solary (France):

Proteomic characterization of two monocyte populations in Chronic Myelomonocytic Leukemia (CMML)

F Von Eggeling (Germany):

Cutaneous T-Cell Lymphma (CTCL) with an outlook to AML

***V Kulasingam (Canada)*:**

Identification and Validation of Candidate Breast Cancer Biomarkers: A Mass Spectrometric Approach

A Goncalves (France):

Breast cancer

N Vasudev (UK):

Novel renal cancer biomarkers - from discovery to validation using biological fluids

Part # 2 – Biomarker Discovery to Validation / Quantification

B Domon (Switzerland):

Tools of quantification in adequation with clinical application MRM

H Langen (Switzerland):

Towards Screening Markers for Colon Rectal Cancer From Biomarker Discovery to Validation in Clinical Sample

WM Gallagher (Ireland):

Validation of Biomarkers of Breast Cancer Progression and Therapeutic Response via Tissue Microarray Technology and Automated Image Analysis

Part # 3 - Bio-informatic tools: biostatistical and bioinformatic

P Roy (France):

Title

B Mertens (Netherlands):

Title

C Bruley (France):

Title

Clinical Proteomics in Oncology

CPO 2008

July 3rd and 4th, 2008 - Dijon, France

July 4th, 2008

8h00 – .

Part # 4 – Sample collection and clinical proteomic studies

S Lehmann (France):

Biobanking and Proteomics discovery programs using the Cerebrospinal fluid (CSF); preanalytical and analytical consideration.

K Wester (Sweden):

A Human protein atlas. The Swedish human proteome resource project.

JD Tissot (Switzerland):

Plasma/serum proteomics: pre-analytical issues

Part # 5 – New development in Proteomic for clinical studies

Plenary lecture

RR Drake (USA):

Beyond Serum Proteomics: Application of MALDI MS Imaging, Glycoproteomic and Quantitative Proteomic Methodologies to Tissues and Proximal Prostatic Fluids for Prostate Cancer Biomarkers

***Part # 5.1** – Purification technologies in adequacy with clinical approaches*

F Berger (France):

Equalizer

J Garin (France):

Tentative strategies for the translation of “omics”-technologies into innovative biomarkers

OJ Semmes (USA):

Glycomics and proteomic studies

P Ducoroy (France):

Depletion of high-abundance proteins in proteomic clinical studies

M Seve (France):

Peptides OFFGEL electrophoresis: a suitable pre-analytical step for complex eukaryotic samples fractionation compatible with quantitative iTRAQ labeling

***Part # 5.2** – Imaging MS*

M Stoeckly (Switzerland): (to be confirmed)

Title

M Salzet (France):

Proteomic Imaging in clinical studies

P Chaurand (USA):

Molecular Imaging of Tissue Sections by MALDI MS: Applications in Cancer Research

***Part # 5.3** - micro arrays and proteomic*

W Boireau (France):

SPR-MS: Surface Plasmon Resonance - Mass Spectrometry in proteomic studies

C Wingren (Sweden):

Design of recombinant antibody microarrays for high-throughput oncoproteomics

D Murphy (Ireland):

Protein arrays as tools for discovery of serum autoantibody markers in cancer